SVON

Sevion Therapeutics, Inc.

A biopharmaceutical company that develops antibody-based therapies for cancer and immunological diseases, using its own discovery platforms to build a pipeline of drug candidates. Born in 1998 as Senesco Technologies, it rebranded to Sevion Therapeutics in 2014 to signal its shift toward next-generation biologics, and later merged with an Israeli drugmaker to become Eloxx Pharmaceuticals. The name "Sevion" has no documented meaning — it was simply chosen for its fresh identity.